Although there are now many new treatments for advanced prostate cancer, hormone therapy (ADT) has remained the standard of care for the last 70 years. While hormone therapy can provide pain relief, it is never curative. Long-term hormone therapy produces decreased quality of life. Men treated with hormone therapy have weight gain, experience impotence, decreased [...]
Not terribly surprising, but recent research shows that less than one-third of all cancer survivors of adult cancers in the United States ever had conversations with their healthcare providers about their psychosocial needs. The latest study showing this was published in the Journal of Clinical Oncology.1 This study was a large population-based study of 1777 [...]
One of the more common side effects of primary prostate cancer treatment with any form of x-ray or ionizing radiation is known as radiation proctitis and the related radiation colitis. Radiation proctitis is inflammation and damage to surrounding organs and tissue caused by stray radiation. Radiation proctitis most commonly occurs after treatment for many different [...]
The New England Journal of Medicine just published a very appealing and easy to understand video about Xofigo dichloride (Radium 223 or Alpharadin), the newly FDA approved treatment for men with advanced prostate cancer who have developed bone metastasis. The short video can be viewed at: N.E. Journal Xofigo Video Joel T. Nowak, M.A., M.S.W.
All of us on androgen deprivation therapy (ADT) know that without testosterone our bodies change and we will develop insulin resistance, the precursor to diabetes. In a just very small, just published study investigators examined if endurance training would improve insulin sensitivity and body composition in men being treated with ADT for their advanced prostate [...]